安罗替尼靶向治疗对人表皮生长因子受体阳性晚期非小细胞肺癌患者疾病控制率的影响

Effect of Targeted Therapy with Anlotinib on Disease Control Rate in Patients with Human Epidermal Growth Factor Receptor Positive Advanced Non-small Cell Lung Cancer

目的:探讨安罗替尼靶向治疗对人表皮生长因子受体(EGFR)阳性晚期非小细胞肺癌(NSCLC)患者疾病控制率的影响。方法:选取九江学院附属医院2018年12月至2020年12月收治的74例EGFR阳性晚期NSCLC患者,运用随机数字表法将患者分为研究组和对照组,各37例。予对照组患者使用顺铂与培美曲塞进行化疗治疗,而研究组患者运用安罗替尼靶向治疗,两组连续治疗6周后,观察两组患者治疗前后肺部转移灶最长径、血管内皮因子(VEGF)水平,比较两组患者疾病控制率和生活质量,此外,对两组不良反应发生率进行比对。结果:治疗后,研究组肺部转移灶最长径比对照组短,且VEGF水平较对照组低(P<0.05),而研究组生活质量评分较对照组更高(P<0.05),研究组患者的疾病控制率为94.59%,比对照组的78.38%更高,研究组不良反应发生率为8.11%,较对照组的27.03%更低(P<0.05)。结论:对EGFR阳性晚期NSCLC患者采取安罗替尼靶向治疗,可有效控制病灶转移并降低VEGF水平,提高疾病控制率,不良反应发生情况较少,安全性良好,且治疗后患者生活质量显著提高,值得进一步应用于临床。

Objective:To investigate the effect of targeted therapy with anlotinib on the disease control rate of patients with human epidermal growth factor receptor(EGFR)-positive terminal non-small cell lung cancer(NSCLC).Methods:A total of 74 EGFR-positive advanced NSCLC patients admitted to Affiliated Hospital of Jiujiang University from December 2018 to December 2020 were selected.The patients were divided into study group and control group,with 37 cases in each group,using a random number table method.Patients in the control group were treated with cisplatin and pemetrexed for chemotherapy,while the patients in the study group were treated with anlotinib.After 6 weeks of continuous treatment,the longest diameter of lung metastases and vascular endothelium Factor(VEGF)level,were observed before and after treatment in the two groups.Compare the disease control rate and quality of life of the two groups of patients,in addition,compare the incidence of adverse reactions between the two groups.Results:After treatment,the longest diameter of lung metastases in the study group was shorter than that in the control group,and the level of VEGF was lower than that in the control group(P<0.05),while the quality of life score of the study group was higher than that of the control group(P<0.05).The disease control rate of patients was 94.59%,which was higher than 78.38%of the control group.The incidence of adverse reactions in the study group was 8.11%,which was lower than 27.03%of the control group(P<0.05).Conclusion:Taking anlotinib targeted therapy for patients with EGFR-positive terminal NSCLC can effectively control tumor metastasis and reduce VEGF level,improve disease control rate,have fewer adverse reactions,good safety,and significantly improve the quality of life of patients after treatment.It is worthy of further clinical application.